Acro Biomedical Co Stock Current Asset
| ACBM Stock | USD 0 0.00 0.00% |
ACRO Biomedical Co fundamentals help investors to digest information that contributes to ACRO Biomedical's financial success or failures. It also enables traders to predict the movement of ACRO Pink Sheet. The fundamental analysis module provides a way to measure ACRO Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ACRO Biomedical pink sheet.
ACRO |
ACRO Biomedical Co Company Current Asset Analysis
ACRO Biomedical's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, ACRO Biomedical Co has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all United States stocks is 100.0% higher than that of the company.
ACRO Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACRO Biomedical's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ACRO Biomedical could also be used in its relative valuation, which is a method of valuing ACRO Biomedical by comparing valuation metrics of similar companies.ACRO Biomedical is currently under evaluation in current asset category among its peers.
ACRO Fundamentals
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 | |||
| Operating Margin | (17.61) % | |||
| Current Valuation | 240.18 M | |||
| Shares Outstanding | 60.04 M | |||
| Shares Owned By Insiders | 49.97 % | |||
| Price To Book | 487.98 X | |||
| Price To Sales | 267.90 X | |||
| Revenue | 1.2 M | |||
| Gross Profit | 259.5 K | |||
| EBITDA | (7.69 M) | |||
| Net Income | 7.7 M | |||
| Cash And Equivalents | 12.11 K | |||
| Total Debt | 59.44 K | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 7.70 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 299.33 K | |||
| Earnings Per Share | (0.20) X | |||
| Beta | 0.92 | |||
| Market Capitalization | 209.55 M | |||
| Total Asset | 761.08 K | |||
| Net Asset | 761.08 K |
About ACRO Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACRO Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACRO Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACRO Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.